David Lebwohl is VP at Intellia Therapeutics, Inc. (NTLA). They have made 10 open-market trades across 1 company since 2021, most recently 2026-03-01.
CIK 0001810882
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NTLA | 131,192 | $1.6M |
Shares reported on the most recent Form 4, priced at the 2026-03-03 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NTLA | SELL | 2026-01-05 | 2026-01-07 | $9.21 | $110K | +19.7% | +14.6% | +26.5% |
| NTLA | SELL | 2025-01-03 | 2025-01-07 | $12.18 | $233K | -17.4% | -15.9% | -45.7% |
| NTLA | SELL | 2024-01-03 | 2024-01-05 | $29.46 | $344K | -10.4% | -11.9% | -11.4% |
| NTLA | SELL | 2023-01-04 | 2023-01-06 | $37.21 | $192K | -13.2% | +14.3% | -6.3% |
| NTLA | SELL | 2022-01-01 | 2022-03-03 | $112.24 | $236K | -16.9% | +8.7% | -38.9% |
| NTLA | SELL | 2021-11-05 | 2021-11-09 | $132.93 | $452K | -5.7% | -18.4% | -29.0% |
| NTLA | SELL | 2021-10-14 | 2021-10-15 | $128.29 | $555K | -0.1% | +2.9% | -31.1% |
| NTLA | SELL | 2021-09-21 | 2021-09-23 | $149.81 | $360K | -15.4% | -12.9% | -18.4% |
| NTLA | SELL | 2021-08-30 | 2021-09-01 | $157.74 | $489K | -6.3% | -18.4% | -30.0% |
| NTLA | SELL | 2021-08-09 | 2021-08-11 | $164.05 | $394K | -0.7% | +0.9% | -13.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.